Physician profile
Mark L Bierhoff
NPI 1568527372
$7,803.70
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,928 · 2020: $1,664 · 2021: $2,669 · 2022: $1,072 · 2023: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,423.29 | 2019-2023 | Skyrizi, Rinvoq, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $739.28 | 2019-2023 | Xifaxan |
| Gilead Sciences, INC. | $716.90 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $603.78 | 2019-2022 | |
| Janssen Biotech, INC. | $573.99 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $409.74 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $266.19 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $215.98 | 2020-2021 | |
| Redhill Biopharma INC. | $206.44 | 2020-2021 | |
| Qol Medical, LLC | $167.79 | 2019-2022 | |
| Pfizer INC. | $156.06 | 2019-2023 | |
| Braintree Laboratories, INC. | $142.38 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $138.58 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $124.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $119.50 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $115.21 | 2021-2023 | Zeposia |
| Ucb, INC. | $100.16 | 2019-2020 | |
| Shionogi INC | $73.17 | 2019-2020 | |
| Concordia Pharmaceuticals INC. | $55.96 | 2019 | |
| Allergan, INC. | $53.30 | 2019-2020 | |
| Steris Corporation | $50.00 | 2019 | |
| Pharmacosmos Therapeutics INC. | $44.46 | 2021 | |
| Daiichi Sankyo INC. | $39.87 | 2019-2020 | |
| Digestive Care, INC. | $38.33 | 2022 | |
| Ardelyx, INC. | $37.40 | 2022-2023 | Ibsrela |
| Shire North American Group INC | $33.74 | 2019 | |
| Ferring Pharmaceuticals INC. | $30.22 | 2021 | |
| Dova Pharmaceuticals | $28.51 | 2019 | |
| Evoke Pharma, INC. | $21.92 | 2021 | |
| Sandoz INC. | $21.87 | 2023 | Hyrimoz |
| Axonics, INC. | $21.28 | 2021 | |
| W. L. Gore & Associates, INC. | $19.49 | 2022 | |
| Mauna Kea Technologies, INC. | $14.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bierhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.